Susquehanna International Group, LLP Tricida, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $12.49 $90,132 - $8.04 Million	-643,800 Reduced 62.69%	383,100 $57,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $2.23 Million - $3.57 Million	262,400 Added 34.32%	1,026,900 $10.8 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $3.57 Million - $5.78 Million	487,900 Added 176.39%	764,500 $7.4 Million
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $675,465 - $976,897	91,900 Added 49.76%	276,600 $2.27 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $651,964 - $1.49 Million	155,600 Added 534.71%	184,700 $1.77 Million

Q1 2021 May 17, 2021	BUY	$4.52 - $7.8 $81,811 - $141,180	18,100 Added 164.55%	29,100 $154,000
Q4 2020 Feb 16, 2021	BUY	$4.37 - $9.46 $48,070 - $104,060	11,000 New	11,000 $78,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.